EVARF logo

Lombard Medical, Inc. (EVARF) Hisse Analizi

Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Lombard Medical, Inc. (EVARF), Healthcare sektöründe faaliyet gösteriyor, son olarak $'dan işlem görüyor ve 0 piyasa değerine sahip. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 47/100 (ihtiyatlı) olarak derecelendirilmiştir.

Son analiz: 17 Mar 2026
47/100 AI Puanı

Lombard Medical, Inc. (EVARF) Sağlık ve Boru Hattı Genel Bakışı

CEOKurt Lemvigh
Çalışanlar113
MerkezDidcot, GB
Halka Arz Yılı2014
SektörHealthcare

Lombard Medical, Inc. focuses on endovascular stent-grafts, particularly Aorfix for complex aortic aneurysms. With a global presence and direct sales model, the company competes in the medical device industry, facing challenges in a market with established players and stringent regulatory requirements, reflected in its negative profit margin.

Veri Kaynağı | Finansal Veriler Kantitatif Analiz NASDAQ Analiz: 17 Mar 2026

Yatırım Tezi

Lombard Medical, Inc. presents a focused investment opportunity within the medical device sector, specifically in the endovascular aneurysm repair market. The company's Aorfix stent-graft addresses a niche segment of AAAs with challenging anatomies, potentially offering a competitive advantage. However, the company's negative profit margin of -255.0% and small market capitalization raise concerns about its financial sustainability. Growth catalysts include expanding market penetration in existing geographies and potential regulatory approvals in new markets. Investors should carefully consider the company's financial position, competitive landscape, and regulatory hurdles before making investment decisions. The company's beta of 0.64 suggests lower volatility than the overall market.

FMP finansallarına ve nicel analizine dayanmaktadır

Temel Önemli Noktalar

  • Market capitalization of $0.00B indicates a micro-cap company with potential for high growth but also significant risk.
  • Negative P/E ratio of -0.00 reflects the company's current lack of profitability.
  • Profit Margin of -255.0% signals significant operational challenges and potential financial instability.
  • Gross Margin of 7.8% suggests limited pricing power and high cost of goods sold.
  • Beta of 0.64 indicates lower volatility compared to the overall market, which may appeal to risk-averse investors.

Rakipler & Benzerleri

Güçlü Yönler

  • Specialized Aorfix stent-graft for complex anatomies.
  • Proprietary delivery systems for precise placement.
  • Direct sales force and distributor network.
  • Focus on state-owned and government-owned hospitals.

Zayıflıklar

  • Negative profit margin and small market capitalization.
  • Limited product portfolio compared to larger competitors.
  • Reliance on a few key products.
  • Dependence on regulatory approvals for market expansion.

Katalizörler

  • Upcoming: Potential regulatory approvals in new geographic markets, expanding market access.
  • Ongoing: Continued adoption of Aorfix stent-graft among vascular surgeons.
  • Ongoing: Expansion of clinical education and training programs.

Riskler

  • Potential: Increased competition from larger medical device companies.
  • Potential: Delays in regulatory approvals.
  • Ongoing: Negative profit margin and financial instability.
  • Ongoing: Limited liquidity due to OTC listing.
  • Potential: Technological obsolescence.

Büyüme Fırsatları

  • Expansion into Emerging Markets: Lombard Medical has the opportunity to expand its geographic footprint into emerging markets with growing healthcare infrastructure and increasing awareness of endovascular procedures. These markets often present less competition and unmet clinical needs, allowing Lombard Medical to gain market share. Successful entry into these markets requires navigating local regulatory requirements and establishing distribution networks. The global market for endovascular aneurysm repair is projected to grow, offering a substantial opportunity for Lombard Medical to capitalize on this trend.
  • Product Line Expansion: Lombard Medical can expand its product line to address a broader range of aortic diseases and anatomies. This could involve developing new stent-grafts, delivery systems, or adjunctive therapies. Expanding the product portfolio would allow Lombard Medical to target a larger patient population and increase its revenue streams. This strategy requires significant investment in research and development, as well as clinical trials to demonstrate safety and efficacy.
  • Strategic Partnerships and Acquisitions: Lombard Medical could pursue strategic partnerships or acquisitions to expand its product portfolio, geographic reach, or technological capabilities. Partnering with larger medical device companies could provide access to established distribution networks and marketing resources. Acquiring complementary technologies or companies could accelerate product development and market entry. Successful partnerships and acquisitions require careful due diligence and integration planning.
  • Focus on Clinical Education and Training: Lombard Medical can invest in clinical education and training programs to increase awareness and adoption of its products among vascular surgeons and interventional radiologists. Providing hands-on training and educational resources can help physicians overcome the learning curve associated with new technologies and techniques. This strategy can lead to increased product utilization and improved clinical outcomes. Clinical education and training programs can be delivered through workshops, conferences, and online platforms.
  • Development of Next-Generation Stent-Graft Technology: Lombard Medical can invest in research and development to develop next-generation stent-graft technology with improved performance, durability, and ease of use. This could involve incorporating new materials, designs, or delivery systems. Developing innovative technology can provide a competitive advantage and attract new customers. This strategy requires significant investment in research and development, as well as clinical trials to demonstrate the superiority of the new technology.

Fırsatlar

  • Expansion into emerging markets.
  • Product line expansion to address broader range of aortic diseases.
  • Strategic partnerships and acquisitions.
  • Development of next-generation stent-graft technology.

Tehditler

  • Competition from larger, established medical device companies.
  • Stringent regulatory requirements and potential delays in approvals.
  • Technological obsolescence.
  • Economic downturns and healthcare budget constraints.

Rekabet Avantajları

  • Proprietary Aorfix stent-graft designed for complex anatomies.
  • Specialized delivery systems for precise stent-graft placement.
  • Established relationships with state-owned and government-owned hospitals.
  • Intellectual property protection for key technologies.

EVARF Hakkında

Founded in 2000 and headquartered in Didcot, UK, Lombard Medical, Inc. is a medical technology company focused on designing, manufacturing, and marketing advanced endovascular stent-grafts for the repair of aortic aneurysms. The company's flagship product, Aorfix, is a unique endovascular stent-graft specifically engineered for the treatment of abdominal aortic aneurysms (AAAs) with significant angulation at the neck of the aneurysm, up to 90 degrees. This addresses a critical need in treating patients with challenging anatomies. In addition to Aorfix, Lombard Medical offers the Altura endovascular stent graft system, designed for standard AAA anatomies. The company also provides specialized delivery systems, including the Aorflex delivery system for precise Aorfix placement and the IntelliFlex LP delivery system to enhance control during deployment. Lombard Medical distributes its products through a direct sales force and distributors, primarily targeting state-owned or government-owned hospitals across the United States, the United Kingdom, Germany, Japan, and other international markets. The company operates in a competitive landscape, facing established medical device companies.

Ne Yaparlar

  • Develops endovascular stent-grafts for aortic aneurysm repair.
  • Manufactures Aorfix stent-graft for complex abdominal aortic aneurysms.
  • Markets Aorfix and Altura stent-graft systems globally.
  • Provides Aorflex and IntelliFlex delivery systems for precise stent-graft placement.
  • Sells products directly and through distributors.
  • Targets state-owned and government-owned hospitals.

İş Modeli

  • Develops and manufactures endovascular stent-grafts.
  • Sells products directly through a sales force and distributors.
  • Generates revenue from stent-graft sales for aortic aneurysm repair.
  • Focuses on state-owned and government-owned hospitals as primary customers.

Sektör Bağlamı

Lombard Medical operates within the global medical device industry, specifically targeting the endovascular aneurysm repair (EVAR) market. This market is driven by an aging population, increasing prevalence of aortic aneurysms, and technological advancements in minimally invasive procedures. The competitive landscape includes larger, established medical device companies with broader product portfolios. Lombard Medical differentiates itself with its Aorfix stent-graft, designed for complex anatomies. The industry is subject to stringent regulatory requirements and ongoing technological innovation.

Kilit Müşteriler

  • State-owned hospitals
  • Government-owned hospitals
  • Vascular surgeons
  • Interventional radiologists
AI Güveni: 71% Güncellendi: 17 Mar 2026

Finansallar

Grafik & Bilgi

Lombard Medical, Inc. (EVARF) hisse senedi fiyatı: Price data unavailable

Son Haberler

EVARF için son haber bulunmamaktadır.

Analist Konsensüsü

Fikir Birliği Derecelendirmesi

EVARF için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.

Fiyat Hedefleri

EVARF için Wall Street fiyat hedefi analizi.

MoonshotScore

47/100

Bu puan ne anlama geliyor?

MoonshotScore, EVARF'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.

Yönetim: Kurt Lemvigh

CEO

Kurt Lemvigh serves as the Chief Executive Officer of Lombard Medical, Inc. His background includes experience in the medical device industry, with a focus on commercialization and market development. Prior to joining Lombard Medical, he held leadership positions at various medical technology companies, where he was responsible for driving revenue growth and expanding market share. He has a proven track record of successfully launching new products and building high-performing teams. His expertise lies in strategic planning, sales and marketing, and business development within the healthcare sector.

Sicil: Since assuming the role of CEO at Lombard Medical, Kurt Lemvigh has focused on streamlining operations, expanding the company's geographic reach, and driving adoption of the Aorfix stent-graft. Key initiatives include strengthening the sales force, establishing new distribution partnerships, and investing in clinical education programs. Under his leadership, the company has faced challenges related to profitability and market competition. His focus remains on achieving sustainable growth and improving financial performance.

EVARF OTC Piyasa Bilgileri

The OTC Other tier represents the lowest tier of the OTC market, indicating that Lombard Medical may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ.

  • OTC Katmanı: OTC Other
  • Açıklama Durumu: Unknown
Likidite: As an OTC stock, EVARF likely suffers from low trading volume and wide bid-ask spreads. This can make it difficult to buy or sell shares quickly and at a desired price. The limited liquidity increases the risk of price volatility and potential losses for investors. Investors should be prepared for potential delays in executing trades and should carefully consider the impact of illiquidity on their investment strategy.
OTC Risk Faktörleri:
  • Limited financial disclosure and transparency.
  • Low trading volume and liquidity.
  • Potential for price manipulation.
  • Higher risk of fraud or mismanagement.
  • Limited regulatory oversight.
Durum Tespiti Kontrol Listesi:
  • Verify the company's registration and legal status.
  • Review available financial statements and disclosures.
  • Assess the company's business model and competitive landscape.
  • Evaluate the management team and their track record.
  • Understand the risks associated with investing in OTC stocks.
  • Consult with a financial advisor.
  • Check for any regulatory actions or legal disputes.
Meşruiyet Sinyalleri:
  • Established history in the medical device industry.
  • Proprietary technology and products.
  • Global presence and distribution network.
  • Experienced management team.

EVARF Hakkında Sıkça Sorulan Sorular

EVARF için değerlendirilmesi gereken temel faktörler nelerdir?

Lombard Medical, Inc. (EVARF) şu anda yapay zeka skoru 47/100, düşük puanı gösteriyor. Temel güçlü yan: Specialized Aorfix stent-graft for complex anatomies.. İzlenmesi gereken birincil risk: Potential: Increased competition from larger medical device companies.. Bu bir finansal tavsiye değildir.

EVARF MoonshotScore'u nedir?

EVARF şu anda MoonshotScore'da 47/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.

EVARF verileri ne sıklıkla güncellenir?

EVARF fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.

Analistler EVARF hakkında ne diyor?

EVARF için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.

EVARF'a yatırım yapmanın riskleri nelerdir?

EVARF için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Increased competition from larger medical device companies.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.

EVARF'ın P/E oranı nedir?

EVARF için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için EVARF'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.

EVARF aşırı değerli mi, yoksa düşük değerli mi?

Lombard Medical, Inc. (EVARF)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.

EVARF'ın temettü verimi nedir?

Lombard Medical, Inc. (EVARF) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.

Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.

Resmi Kaynaklar

Analiz güncellendi AI Puanı günlük olarak yenilenir
Veri Kaynakları ve Metodoloji
Piyasa verileri Financial Modeling Prep ve Yahoo Finance tarafından sağlanmaktadır. AI analizi Stock Expert AI tescilli algoritmaları ile yapılmaktadır. Teknik göstergeler endüstri standardı hesaplamalarla üretilmektedir. Son güncelleme: .

Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.

Analiz Notları
  • Information is based on available data and may be subject to change.
  • OTC market data may be less reliable than exchange-listed data.
Veri Kaynakları

Popüler Hisseler